ストックスクリーナーアプリを入手
0.8829
2.44%
-0.0221
アフターアワーズ：
.87
-0.0129
-1.46%
前日終値:
$0.905
開ける：
$0.89
24時間の取引高:
177.33K
Relative Volume:
0.58
時価総額：
$66.53M
収益：
$9.53M
当期純損益:
$-44.61M
株価収益率:
-0.9702
EPS:
-0.91
ネットキャッシュフロー:
$-38.32M
1週間 パフォーマンス:
-1.90%
1か月 パフォーマンス:
+12.33%
6か月 パフォーマンス:
-40.74%
1年 パフォーマンス:
+25.54%
1日の値動き範囲:
$0.85
$0.92
1週間の範囲:
$0.8387
$0.9499
52週間の値動き範囲:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
CUE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.8829 | 68.19M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-13 | 開始されました | Jefferies | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2022-11-21 | 開始されました | Piper Sandler | Overweight |
| 2022-01-13 | 開始されました | H.C. Wainwright | Buy |
| 2022-01-03 | 開始されました | Craig Hallum | Buy |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-04-09 | 開始されました | Stifel | Buy |
| 2020-01-28 | 開始されました | BTIG Research | Buy |
| 2020-01-22 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Cue Biopharma Inc (CUE) 最新ニュース
Is Cue Biopharma Inc. stock overvalued or undervaluedExplosive trading opportunities - jammulinksnews.com
Buy Signal for Cue Biopharma Inc. Stock Key Technical Indicators to WatchSafer Investing With Bigger Upside - Newser
Why Cue Biopharma Inc. stock attracts strong analyst attentionLow Risk Trade Timing Signals - Newser
Will Cue Biopharma Inc. stock benefit from interest rate changesFree Investment Community - Newser
Why Cue Biopharma Inc. stock is on top investor watchlistsFree Consultation - Newser
How Cue Biopharma Inc. stock performs during market volatilityWealth Accumulation Stock List - Newser
What makes Cue Biopharma Inc. stock price move sharplyHigh Confidence Trade Setups - Newser
Will Cue Biopharma Inc. stock split in the near futureConsistently high yield - jammulinksnews.com
What analysts say about Cue Biopharma Inc. stockConsistently outstanding ROI - PrintWeekIndia
What analysts say about Cue Biopharma Inc. stock outlookFree Consultation - jammulinksnews.com
What drives Cue Biopharma Inc. stock priceFree High-Return Strategy Alerts - Autocar Professional
Pancreatic Cancer Market to Show Remarkable Growth Trends from - openPR.com
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
Is Cue Biopharma Inc. a good long term investmentBreakthrough profits - jammulinksnews.com
Cue Biopharma Inc. Stock Analysis and ForecastPhenomenal investment performance - jammulinksnews.com
Cue Biopharma shares fall 4.67% premarket despite reporting new complete response in clinical trial. - AInvest
Cue Biopharma Reports New Complete Response and Confirmed 50% Overall Response Rate in Ongoing Phase 1 Trial of CUE-101 and Pembrolizumab in Recurrent/Metastatic HPV+ Head and Neck Cancer - The Manila Times
Breakthrough: New Cancer Drug Shows 88% Survival Rate in Head and Neck Cancer Phase 1 Trial - Stock Titan
How Olin Corporation stock performs during market volatilityCapital Protected Stock Selections - Newser
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Shares - Newser
Cue Biopharma Inc (CUE) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):